Traditional Chinese medicine composition for clearing away lung-heat and relieving sore-throat, pharmaceutical preparation and application
A traditional Chinese medicine composition addresses the need for ALI treatment by alleviating neutrophil infiltration and reducing inflammatory responses, effectively treating ALI with minimal side effects.
Patent Information
- Application Number
- CN202411170868.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-23
AI Technical Summary
There is an urgent need for safe and effective treatment drugs for acute lung injury (ALI), as existing treatments like respiratory support and drug therapy have high mortality rates and no clinically determined safe drugs are available.
A traditional Chinese medicine composition comprising Forsythia suspensa, Honeysuckle, Mulberry leaves, Scrophularia ningpoensis, Ophiopogon japonicus, and Licorice is developed, which alleviates neutrophil infiltration, reduces inflammatory responses, and inhibits pulmonary edema, providing a scientific basis for treating ALI.
The Chinese medicine composition effectively reduces lung tissue damage, inflammatory factor levels, and improves ALI symptoms, offering a safe and effective therapeutic option for ALI.
Smart Images

Figure CN119074852A_ABST
Abstract
Description
Technical Field
[0001] The present invention generally relates to the field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition, a pharmaceutical preparation and a use thereof for clearing the lungs and relieving throat pain. Background Art
[0002] Acute lung injury (ALI) is caused by increased alveolar and capillary permeability due to various reasons, resulting in alveolar and interstitial edema, resulting in common clinical respiratory hazards such as hypoxic respiratory system disorders. Severe cases may develop into acute respiratory distress syndrome. Although many treatment strategies have been developed for ALI, supportive treatment is the main treatment in clinical practice, such as respiratory support, extracorporeal life support, and drug therapy, and the mortality rate of ALI is still very high. As for drug therapy, no safe and effective ALI treatment drugs have been clinically determined. There is an urgent need to develop a Chinese medicine composition for the treatment of acute lung injury. Summary of the invention
[0003] Based on the above background, the present application provides a traditional Chinese medicine composition for clearing the lungs and relieving sore throat, wherein the traditional Chinese medicine composition is made of the following traditional Chinese medicine raw materials, by weight: 20-40 parts of Forsythia suspensa, 20-40 parts of Honeysuckle, 20-40 parts of Mulberry leaves, 20-40 parts of Scrophularia ningpoensis, 7-11 parts of Ophiopogon japonicus and 4-8 parts of Licorice.
[0004] On the other hand, the present application also provides a pharmaceutical preparation, wherein the pharmaceutical preparation comprises the Chinese medicine composition or an extract thereof described herein.
[0005] In another aspect, the present application also provides use of the Chinese medicine composition described herein or the pharmaceutical preparation described herein in the preparation of a medicament for treating and / or preventing acute lung injury.
[0006] In the mouse animal model experiment, the Chinese medicine composition described in this article can not only alleviate the phenomenon of neutrophil infiltration in the alveolar lavage fluid caused by LPS and reduce the inflammatory response; it also helps to improve LPS-induced lung tissue pathological damage, maintain the integrity of the alveolar structure, inhibit pulmonary edema, downregulate the level of inflammatory factors in the alveolar lavage fluid, and inhibit the expression of inflammatory factors in lung tissue, thereby preventing and treating acute lung injury caused by LPS. This application can provide a scientific basis and safe and effective therapeutic drugs for the clinical treatment of acute lung injury. This application studies the pharmacological effects of the Chinese medicine composition described in this article on acute lung injury, and finds that it can alleviate the condition, control symptoms and reduce mortality, providing a scientific basis for the clinical prevention and / or treatment of acute lung injury and providing effective therapeutic drugs.
[0007] Other features and advantages of the present application will be described in the following description, and partly become apparent from the description, or be understood by implementing the present application. Other advantages of the present application can be realized and obtained by the schemes described in the description and the drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] The accompanying drawings are used to provide an understanding of the technical solution of the present application and constitute a part of the specification. Together with the embodiments of the present application, they are used to explain the technical solution of the present application and do not constitute a limitation on the technical solution of the present application.
[0009] Figure 1 HE staining observation (20×) of the lungs of each group of mice in Example 3 of the present application.
[0010] Figure 2 The infiltration of neutrophil CD11b and Ly6G in the bronchoalveolar lavage fluid of each group of mice in Example 4 of the present application is shown.
[0011] Figure 3 The total amount of lung exudate cells in the bronchoalveolar lavage fluid of each group of mice in Example 4 of the present application is shown.
[0012] Figure 4 The figure shows the number of neutrophils in the alveolar lavage fluid of each group of mice in Example 4 of the present application.
[0013] Figure 5 The graph shows the expression level of IL-6 in the bronchoalveolar lavage fluid of each group of mice in Example 5 of the present application.
[0014] Figure 6 The figure shows the expression level of TNF-α in the bronchoalveolar lavage fluid of each group of mice in Example 5 of the present application.
[0015] Figure 7 The graph shows the expression level of IL-1β in the bronchoalveolar lavage fluid of each group of mice in Example 5 of the present application.
[0016] Figure 8 The expression levels of IL-6 mRNA in the lung tissues of each group of mice in Example 5 of the present application are shown.
[0017] Fig. 9 The expression levels of TNF-α mRNA in the lung tissues of each group of mice in Example 5 of the present application are shown.
[0018] Fig.10 The expression levels of IL-1β mRNA in the lung tissues of each group of mice in Example 5 of the present application are shown. DETAILED DESCRIPTION
[0019] Unless otherwise stated, the technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the application belongs. When a certain amount, concentration or other value or parameter is expressed in the form of a range, a preferred range, or a preferred upper numerical limit and a preferred lower numerical limit, it should be understood that it is equivalent to specifically revealing any range by combining any pair of upper range limits or preferred numerical values with any lower range limit or preferred numerical value, regardless of whether the range is specifically disclosed. Unless otherwise stated, the numerical ranges listed herein are intended to include the endpoints of the range and all integers and fractions (decimals) within the range.
[0020] The terms "about" and "approximately" when used with a numerical variable generally refer to the value of that variable and all values of that variable are within experimental error (e.g., within a 95% confidence interval for the mean) or within ±10% of the specified value, or a wider range.
[0021] The expression "comprising" or its synonymous similar expressions "including", "containing" and "having" etc. are open-ended and do not exclude additional unrecited elements, steps or ingredients. The expression "consisting of excludes any element, step or ingredient not specified. The expression "consisting essentially of means that the scope is limited to the specified elements, steps or ingredients, plus the optional elements, steps or ingredients that do not materially affect the basic and novel characteristics of the claimed subject matter. It should be understood that the expression "comprising" encompasses the expressions "consisting essentially of" and "consisting of".
[0022] The expression "at least one" or "one or more" means 1, 2, 3, 4, 5, 6, 7, 8, 9 or more.
[0023] Since the occurrence of pneumonia caused by the new coronavirus infection, traditional Chinese medicine has participated in the treatment of the whole process and made important contributions to the prevention and treatment of the disease. Traditional Chinese medicine has many years of experience in preventing and treating epidemic diseases, is safe and effective, has strong accessibility, and can effectively treat respiratory diseases. The Chinese medicine composition of this application is developed from the classic prescription Yinqiaosan, and its prescription principle is that honeysuckle is sweet and cold, clearing heat and detoxifying, and cooling and dispersing wind and heat; forsythia is bitter and cold, clearing heat and detoxifying, and dispersing swelling and dispersing knots; mulberry leaves are sweet, bitter, and cold, evacuating upper Jiao wind and heat, and are good at walking lung collaterals to clear the lungs and moisten dryness. Honeysuckle, forsythia, and mulberry leaves are compatible with pungent and cool wind, clearing heat and moistening the lungs; Scrophularia is bitter and slightly cold, cools blood, nourishes yin and reduces fire, and detoxifies and relieves throat and resolves knots; Ophiopogon japonicus nourishes yin and clears the lungs, and licorice clears heat and detoxifies, relieves throat and relieves pain, and harmonizes various medicines. The total prescription has the effects of clearing wind and clearing the lungs, detoxifying and relieving throat, and is suitable for lung inflammation damage caused by exogenous wind-heat, throat discomfort, swelling and pain, hoarseness and other symptoms.
[0024] On the one hand, the present application provides a traditional Chinese medicine composition for clearing the lungs and relieving sore throat, wherein, by weight, the traditional Chinese medicine composition comprises: 20-40 parts of Forsythia suspensa, 20-40 parts of Honeysuckle, 20-40 parts of Mulberry leaves, 20-40 parts of Scrophularia ningpoensis, 7-11 parts of Ophiopogon japonicus and 4-8 parts of Licorice.
[0025] In some embodiments, the Chinese medicine composition is made of the following Chinese medicine raw materials, by weight: 20-40 parts of Forsythia suspensa, 20-40 parts of Honeysuckle, 20-40 parts of Morus alba, 20-40 parts of Scrophularia ningpoensis, 7-11 parts of Ophiopogon japonicus and 4-8 parts of Licorice.
[0026] In some embodiments, the Chinese medicine composition is made of the following Chinese medicine raw materials, by weight: 25-35 parts of Forsythia suspensa, 25-35 parts of Honeysuckle, 25-35 parts of Morus alba, 25-35 parts of Scrophularia ningpoensis, 8-10 parts of Ophiopogon japonicus and 5-7 parts of Licorice.
[0027] In some embodiments, the Chinese medicine composition is made of the following Chinese medicine raw materials, by weight: 30 parts of Forsythia suspensa, 30 parts of Honeysuckle, 30 parts of Morus alba, 30 parts of Scrophularia ningpoensis, 9 parts of Ophiopogon japonicus and 6 parts of Licorice.
[0028] On the other hand, the present application also provides a pharmaceutical preparation, wherein the pharmaceutical preparation comprises the Chinese medicine composition or an extract thereof described herein.
[0029] In some embodiments, the extract is an aqueous extract or an alcoholic extract of the herbal composition described herein.
[0030] In some embodiments, the pharmaceutical formulation further comprises a pharmaceutically acceptable excipient.
[0031] In some embodiments, the excipients are selected from one or more of pharmaceutically acceptable solvents, solubilizers, co-solvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flavoring agents, preservatives, suspending agents, coating materials, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, thickeners, inclusion agents, humectants, flocculants and deflocculating agents, filter aids, release retardants, polymer skeleton materials and film-forming materials.
[0032] In some embodiments, the dosage form of the pharmaceutical preparation is a tablet, a capsule, a powder, a pill, a granule, an oral liquid, a syrup, a decoction, a suppository, a gel, a spray or an injection. In some embodiments, the dosage form of the pharmaceutical preparation in the present application includes capsules, tablets, pills, liquids, powders, granules, fine granules, film coatings, pills, lozenges, sublingual agents, peptizers, buccal preparations, pastes, syrups, suspensions, elixirs, emulsions, coatings, ointments, plasters, poultices, transdermal preparations, lotions, inhalants, aerosols, injections and suppositories.
[0033] In some embodiments, the pharmaceutical formulation is administered orally, intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, intravesically, intratumorally, topically, intramuscularly, subcutaneously, mucosally, by inhalation, injection, infusion, or any combination thereof.
[0034] In another aspect, the present application also provides use of the Chinese medicine composition described herein or the pharmaceutical preparation described herein in the preparation of a medicament for treating and / or preventing acute lung injury.
[0035] In another aspect, the present application also provides a method for treating and / or preventing acute lung injury, the method comprising: administering the Chinese medicine composition described herein or the pharmaceutical preparation described herein to a subject.
[0036] In some embodiments, the subject is a human, rat, mouse, cat, dog, horse, sheep, cow, monkey. In some embodiments, illustrative examples of subjects include primates, particularly humans, companion animals such as cats and dogs and similar animals, working animals such as horses, donkeys and similar animals, livestock animals such as sheep, cattle, goats, pigs and similar animals, laboratory test animals such as rabbits, mice, rats, guinea pigs, hamsters and similar animals, and captive wild animals such as captive wild animals in zoos and safari parks, deer, dingoes and similar animals. In some embodiments, the subject is a human.
[0037] This application uses experimental means to investigate the protective effect of the Chinese medicine composition described herein on lipopolysaccharide (LPS)-induced acute lung injury. The Chinese medicine composition described herein significantly improves LPS-induced lung tissue pathological damage; and further confirms that its pharmacological effect is achieved by alleviating the phenomenon of neutrophil infiltration in alveolar lavage fluid caused by LPS, downregulating the level of proinflammatory factors in alveolar lavage fluid, and inhibiting the expression of inflammatory factors in lung tissue. Based on the above new properties of the Chinese medicine composition described herein, this application has determined its new use in the preparation of drugs for the treatment and / or prevention of acute lung injury, which has good efficacy, small toxic side effects, and good prospect value.
[0038] The present application describes a plurality of embodiments, but the description is exemplary rather than restrictive, and it is apparent to those skilled in the art that there may be more embodiments and implementations within the scope of the embodiments described in the present application. Although many possible feature combinations are shown in the drawings and discussed in the specific embodiments, many other combinations of the disclosed features are also possible. Unless specifically limited, any feature of any embodiment may be used in combination with any other feature in any other embodiment, or may replace any other feature in any other embodiment.
[0039] The present application includes and contemplates combinations of features known to those of ordinary skill in the art. The embodiments and features disclosed in the present application may also be combined with any conventional features to form a unique invention scheme defined by the claims. Any feature of any embodiment may also be combined with features from other invention schemes to form another unique invention scheme defined by the claims. Therefore, it should be understood that any feature shown and / or discussed in the present application may be implemented individually or in any appropriate combination. Therefore, except for the limitations made according to the attached claims and their equivalents, the embodiments are not subject to other restrictions. In addition, various modifications and changes may be made within the scope of protection of the attached claims.
[0040] In addition, when describing representative embodiments, the specification may have presented the method and / or process as a specific sequence of steps. However, to the extent that the method or process does not rely on the specific order of the steps described herein, the method or process should not be limited to the steps of the specific order described. As will be understood by those of ordinary skill in the art, other sequences of steps are also possible. Therefore, the specific sequence of the steps set forth in the specification should not be interpreted as a limitation to the claims. In addition, the claims for the method and / or process should not be limited to the steps of performing them in the order written, and those skilled in the art can easily understand that these sequences can be changed and still remain within the spirit and scope of the embodiments of the present application.
[0041] The experimental methods in the following examples without specifying specific conditions are usually measured according to national standards. The experimental materials in the following examples without specifying the source are all commercially available raw materials. The equipment used in each step in the following examples is conventional equipment. If there is no corresponding national standard, it is carried out according to the general international standards, conventional conditions, or according to the conditions recommended by the manufacturer. Unless otherwise defined or specified, all professional and scientific terms used in this application have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equal to the recorded content can be applied to the method of this application.
[0042] Example
[0043] The relevant materials used in the examples are as follows:
[0044] 1. Reagents and Materials
[0045] Positive control drugs: dexamethasone (MCE, HY-14648), Jinhua Qinggan granules;
[0046] Lipopolysaccharide (LPS) (Sigma, L2880), PBS (macgene, CC008), APC-anti-mouse CD11b antibody (BioLegend, 101212), PE-anti-mouse Ly6G antibody (BD Pharmingen, 551461), mouse TNF-α pre-coated ELISA Kit, mouse IL-6 pre-coated ELISA Kit, mouse IL-1β pre-coated ELISA Kit (DAKEWE, 1217202, 1210602, 1210122), 0.9% NaCl injection.
[0047] 2. Experimental Animals
[0048] Healthy male C57BL / 6 mice (8 weeks old, weighing 20±2 g) were purchased from Spefoc Biotechnology Co., Ltd. All mice were placed in an environment with a light / dark cycle of 12 h each (room temperature 25°C, humidity 50%) and had free access to food and water for 5 days of adaptive feeding.
[0049] Example 1. Pharmaceutical preparation
[0050] In the embodiments, the Chinese medicine composition used herein is a granule of the Chinese medicine composition.
[0051] Preparation of Chinese medicine composition granules: The raw materials: 30g of Forsythia suspensa, 30g of honeysuckle, 30g of mulberry leaves, 30g of Scrophularia ningpoensis, 9g of Radix Ophiopogonis, 6g of Radix Glycyrrhizae are converted into formula granules according to the implementation standard of Chinese Pharmacopoeia formula granules: 9.1g of Forsythia suspensa, 10g of honeysuckle, 7.5g of mulberry leaves, 20g of Scrophularia ningpoensis, 8.18g of Radix Ophiopogonis, 2g of Radix Glycyrrhizae. Then the formula granules are mixed to obtain the granules of the Chinese medicine composition of the present application.
[0052] In previous research work, the Chinese medicine composition of the present application has been clinically used in adults, and it was found that the maximum dosage for adults was 56.78 g / day (calculated by weight of the formula granules, 135 g / day by weight of the raw material drug). Based on an adult weight of 70 kg, the dose for mice is 7.3814 g / kg (calculated by weight of the formula granules, 17.55 g / day by weight of the raw material drug).
[0053] LPS solution (4 mg / kg): 8 mg of LPS powder was weighed and dissolved in 5 mL of 0.9% NaCl injection to make a 1.6 mg / mL LPS solution.
[0054] Low dose of Chinese medicine composition granules (7.4 g / kg): 1 times the clinical dose, weigh 3.7 g of Chinese medicine composition granules and dissolve them in 5 mL of 0.9% NaCl injection solution, and the gavage volume for each mouse is 0.2 mL.
[0055] High dose of Chinese medicine composition granules (14.8 g / kg): 2 times the clinical dose, weigh 7.4 g of Chinese medicine composition granules and dissolve them in 5 mL of 0.9% NaCl injection solution, and the gavage volume for each mouse is 0.2 mL.
[0056] Positive control: Dexamethasone (5 mg / kg): Weigh 2.5 mg of dexamethasone and dissolve it in 5 mL of 0.9% NaCl injection solution. The intraperitoneal injection volume for each mouse is 0.2 mL.
[0057] Jinhua Qinggan Granules (6 g / kg): Weigh 3 g of Jinhua Qinggan Granules and dissolve them in 5 mL of 0.9% NaCl injection solution. The gavage volume for each mouse is 0.2 mL.
[0058] Example 2. Animal Experiment
[0059] In the embodiments of the present application, the Chinese medicine composition granules are also called Qingfei Liyan Decoction (Q).
[0060] Mice were randomly divided into 7 groups, including blank control (CON), blank + Qingfei Liyan Decoction (CQ), LPS (LPS), LPS + Qingfei Liyan Decoction (7.4 g / kg) (QL), LPS + Qingfei Liyan Decoction (14.8 g / kg) (QH), LPS + dexamethasone (5 mg / kg) (DEX), and LPS + Jinhua Qinggan Granule (6 g / kg) (JHQG). Mice in the CQ, QL, and QH groups were pre-gavaged with Qingfei Liyan Decoction for 5 days, those in the JHQG group were pre-gavaged with Jinhua Qinggan Granule for 5 days, those in the DEX group were intraperitoneally injected with dexamethasone for 5 days, and the mice in the CON and LPS groups were gavaged with an equal amount of normal saline at the same time. Six hours after the last administration, mice were anesthetized by intraperitoneal injection of 1% sodium pentobarbital, 50 μL LPS (4 mg / kg) was instilled into the trachea of the LPS, QL, QH, DEX, and JHQG groups, and the same amount of saline was instilled into the trachea of the CON and CQ groups. After the mice gradually woke up, the CQ, QL, and QH groups were gavaged with Qingfei Liyan Decoction, the DEX group was intraperitoneally injected with dexamethasone, and the JHQG group was gavaged with Jinhua Qinggan Granules. After 12 hours of treatment, the mice were euthanized, and lung tissues and bronchoalveolar lavage fluid were collected. The left lung tissue was fixed in 4% paraformaldehyde solution for 24 hours, and then embedded in paraffin after alcohol dehydration. After trimming the tissue, it was sectioned at a thickness of 4-8 μm, and hematoxylin-eosin staining (HE) was performed. The right lung tissue was placed in a cryopreservation tube for homogenization for tissue real-time quantitative fluorescence qPCR.
[0061] After euthanasia of mice, the chest cavity and trachea were exposed, the trachea was ligated, and the lungs were flushed 3 times with 1 mL of pre-cooled PBS to obtain bronchoalveolar lavage fluid (BALF). 10 μL of BALF was aspirated and counted with a cell counting plate, and the BALF that had been counted was centrifuged at 4°C (1500 rpm, 10 min), and the cell-free supernatant was collected and stored at -80°C for inflammatory factor analysis. 100 μL of pre-cooled PBS was added to the cell pellet, and the cell pellet was resuspended for flow cytometry APC-CD11b / PE-Ly6G to detect neutrophil infiltration. 2 μL of APC-CD11b and PE-Ly6G were added to the cell suspension, incubated at room temperature in the dark for 30 min, centrifuged at 4°C (1200 rpm, 5 min), and the supernatant was discarded. After being fully washed with PBS, the cells were resuspended in 200 μL of 2% paraformaldehyde and placed at 4°C for detection using FACSCantoⅡ flow cytometry analyzer (BD Biosciences, USA).
[0062] BALF supernatant was prepared for ELISA detection. ELISA kits were used to detect the levels of TNF-α, IL-6, and IL-1β, and the concentrations of inflammatory factors were calculated using the standard curve.
[0063] Total RNA from lung tissues was extracted using Trizol and reverse transcribed into complementary DNA (cDNA) using RT SuperMix according to the instructions, and then amplified using SYBR qPCR and fluorescent quantitative real-time PCR was performed using Quantstudio 6Flex PCR Analyzer.
[0064] Example 3. Comparison of HE staining of lungs of mice in each group
[0065] The staining results are shown in Figure 1 In the LPS group, the alveolar structure was destroyed and the alveolar wall was thickened, resulting in a large number of inflammatory cells infiltrating into the alveolar lavage fluid, indicating that the acute lung injury model was successfully established. Compared with the ALI model group, the degree of lung injury in the QL group, QH group, DEX group, and JHQG group mice was alleviated to varying degrees. Histopathological analysis showed the protective effect of Qingfei Liyan Decoction.
[0066] Example 4. Analysis of neutrophil infiltration in bronchoalveolar lavage fluid of mice in each group
[0067] like Figure 2 , Figure 3 , Figure 4As shown in the figure, APC-CD11b and PE-Ly6G are markers of neutrophils. Flow cytometry detection of APC-CD11b and PE-Ly6G in BALF showed that after LPS treatment, a large number of CD11b+, Ly6G+ neutrophils were present in the lungs. There was no significant difference between the CON group and the CQ group, indicating that the safety of Qingfei Liyan Decoction in animals has been confirmed. Qingfei Liyan Decoction, dexamethasone, and Jinhua Qinggan Granules had a certain inhibitory effect on LPS-induced neutrophil infiltration and lung exudate cells (AECs).
[0068] Example 5. Comparison of alveolar lavage fluid and lung tissue inflammation in each group of mice
[0069] The levels of IL-6, TNF-α, and IL-1β in BALF supernatant were detected by enzyme-linked immunosorbent assay (ELISA) kit. Compared with the CON group, the secretion of inflammatory mediators in BALF in the LPS group was significantly increased. Compared with the LPS group, the levels of inflammatory factors in the Qingfei Liyan Decoction treatment group, DEX group, and JHQG group were significantly decreased ( Figure 5-Figure 7 ).according to Figure 8-Figure 10 It can be analyzed that all inflammatory cytokine mRNA detected in lung tissue of LPS group was upregulated, but the treatment group could reduce the expression of pro-inflammatory factor mRNA in lung tissue, especially at high dose of Qingfei Liyan Decoction. These results indicate that Qingfei Liyan Decoction can improve LPS-induced acute lung injury, reduce inflammatory cell infiltration and reduce the secretion of inflammatory factors.
[0070] In summary, the treatment of the Chinese medicine composition of the present application can reduce the degree of lung damage such as alveolar wall thickening and alveolar structure destruction caused by LPS, reduce the infiltration of neutrophils in BALF, and reduce the levels of inflammatory factors IL-6, TNF-α, and IL-1β in BALF. Reduce the expression of proinflammatory factors IL-6, TNF-α, and IL-1βmRNA in lung tissue, and the QH group is better than the JHQG group in inflammatory indicators. Jinhua Qinggan Granules have played an important role in the treatment of pneumonia caused by new coronavirus infection and have shown good clinical efficacy. It can be seen that the Chinese medicine composition of the present application can also be further developed as a clinical drug for the prevention and / or treatment of lung diseases. The embodiments of the present application have confirmed that the Chinese medicine composition of the present application has a good preventive and / or therapeutic effect on acute lung injury.
Claims
1. A Chinese medicine composition for clearing the lungs and relieving throat pain, wherein: The Chinese medicine composition is prepared from the following Chinese medicine raw materials by weight: 20-40 parts of Forsythia suspensa, 20-40 parts of Honeysuckle, 20-40 parts of Morus alba, 20-40 parts of Scrophularia ningpoensis, 7-11 parts of Ophiopogon japonicus and 4-8 parts of Licorice.
2. The Chinese medicine composition according to claim 1, wherein The Chinese medicine composition is prepared from the following Chinese medicine raw materials by weight: 25-35 parts of Forsythia suspensa, 25-35 parts of Honeysuckle, 25-35 parts of Morus alba, 25-35 parts of Scrophularia ningpoensis, 8-10 parts of Ophiopogon japonicus and 5-7 parts of Licorice.
3. The Chinese medicine composition according to claim 2, wherein The Chinese medicine composition is prepared from the following Chinese medicine raw materials by weight: 30 parts of Forsythia suspensa, 30 parts of Honeysuckle, 30 parts of Morus alba, 30 parts of Scrophularia ningpoensis, 9 parts of Ophiopogon japonicus and 6 parts of Licorice.
4. A pharmaceutical preparation, wherein The pharmaceutical preparation comprises the Chinese medicine composition or extract thereof according to any one of claims 1 to 3.
5. The pharmaceutical preparation according to claim 4, wherein The extract is a water extract or an alcohol extract of the traditional Chinese medicine composition.
6. The pharmaceutical preparation according to claim 4, wherein The pharmaceutical preparation further comprises pharmaceutically acceptable excipients.
7. The pharmaceutical preparation according to claim 6, wherein The excipients are selected from one or more of pharmaceutically acceptable solvents, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flavoring agents, preservatives, suspending agents, coating materials, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, thickeners, inclusion agents, humectants, flocculants and deflocculating agents, filter aids, release retardants, polymer skeleton materials and film-forming materials.
8. The pharmaceutical preparation according to claim 4, wherein The dosage form of the pharmaceutical preparation is tablet, capsule, powder, mixture, pill, granule, oral liquid, syrup, decoction, suppository, gel, spray or injection.
9. Use of the Chinese medicine composition according to any one of claims 1 to 3 or the pharmaceutical preparation according to any one of claims 4 to 8 in the preparation of a medicament for treating and / or preventing acute lung injury.
Citation Information
Patent Citations
Chinese herbal compound particle for treating radiation-induced lung injury and preparation method thereof
CN109893613A
Application of traditional Chinese medicine composition in preparation of medicine for treating acute lung injury
CN113384647A
